Monalisa Moody, Author at Lucius Partners

Lucius Partners Portfolio Company PD Theranostics, Inc. Signs Letter of Intent to Merge with Fulton Ventures Corp.

New York, NY 6 March 2023, — Lucius Partners, LLC today announced that its portfolio company, PD Theranostics, Inc. (“PDTx”), has signed a non-binding letter of intent (the “LOI”) to combine with […]

Lucius Partners Portfolio Company PD Theranostics, Inc. Signs Letter of Intent to Merge with Fulton Ventures Corp.Monalisa Moody2023-04-14T21:20:00-04:00

Lucius Partners Portfolio Company AerWave Medical, Inc. Announces it Initiated Filing of Regulatory Documents for First in Man Studies

Important step in improving patient care in treatment of COPD & Asthma

NEW YORK, April 4, 2023 (GLOBE NEWSWIRE) — Lucius Partners, LLC (“LP”), […]

Lucius Partners Portfolio Company AerWave Medical, Inc. Announces it Initiated Filing of Regulatory Documents for First in Man StudiesMonalisa Moody2023-04-14T21:37:01-04:00

Lucius Partners Portfolio Company AerWave Medical, Inc. Announces it Has Filed Two New Patent Applications

Further Advances IP Portfolio

Address Key Issues in Treatment of COPD & Asthma

NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) — Lucius Partners, LLC (“LP”), today announced […]

Lucius Partners Portfolio Company AerWave Medical, Inc. Announces it Has Filed Two New Patent ApplicationsMonalisa Moody2023-04-14T21:37:25-04:00

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial

Self Assembling Vaccine […]

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology TrialMonalisa Moody2023-04-14T21:52:14-04:00

Lucius Partners Announces the Addition of Centaur Bio, Inc. to the Portfolio

Centaur ‘s precision medicine technology, licensed from Duke University School of Medicine, transports difficult to deliver agents across the blood brain barrier

Multiple Oncology and CNS indications; first IND expected to be open in 2Q23

[…]

Lucius Partners Announces the Addition of Centaur Bio, Inc. to the PortfolioMonalisa Moody2023-04-06T21:58:18-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research SymposiumMonalisa Moody2023-04-14T21:52:27-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge StudyMonalisa Moody2023-04-14T21:52:36-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific Advisor

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific AdvisorMonalisa Moody2023-04-14T21:52:45-04:00

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-OncologyMonalisa Moody2023-04-14T21:52:55-04:00

PD Theranostics, Inc., a Lucius Partners Company, Announces Key License Agreement and Provides Corporate Update

PD Theranostics, Inc., a Lucius Partners Company, Announces Key License Agreement and Provides Corporate UpdateMonalisa Moody2023-04-14T21:20:30-04:00

About Monalisa Moody